Tyra Biosciences, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
TYRA$21.00-5.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders' Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2023 | 43,024,634 | $4 | $368,707 | $381 | $(164,830) | $204,262 |
| Issuance of common stock under Private Placement, net of issuance costs of $0.2 million | 9,286,023 | 1 | 120,557 | — | — | 120,558 |
| Issuance of pre-funded warrants, net of issuance costs of $0.2 million | — | — | 79,022 | — | — | 79,022 |
| Issuance of common stock under benefit plans | 135,972 | — | 484 | — | — | 484 |
| Vesting of shares of common stock subject to repurchase | 27,904 | — | 17 | — | — | 17 |
| Stock-based compensation | — | — | 4,115 | — | — | 4,115 |
| Unrealized loss on marketable securities available-for-sale, net | — | — | — | (387) | — | (387) |
| Net loss | — | — | — | — | (18,192) | (18,192) |
| Balance at March 31, 2024 | 52,474,533 | $5 | $572,902 | $(6) | $(183,022) | $389,879 |
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 50,749,945 | $5 | $593,687 | $770 | $(251,311) | $343,151 |
| Issuance of common stock pursuant to pre-funded warrant exercise | 2,000,069 | — | — | — | — | — |
| Issuance of common stock under benefit plans | 335,626 | — | 2,187 | — | — | 2,187 |
| Vesting of shares of common stock subject to repurchase | 4,317 | — | 3 | — | — | 3 |
| Stock-based compensation | — | — | 6,422 | — | — | 6,422 |
| Unrealized loss on marketable securities available-for-sale, net | — | — | — | (82) | — | (82) |
| Net loss | — | — | — | — | (28,147) | (28,147) |
| Balance at March 31, 2025 | 53,089,957 | $5 | $602,299 | $688 | $(279,458) | $323,534 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.